| Metformin in polycystic ovary syndrome. | |
| | |
MedLine Citation:
|
PMID: 20840272 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Polycystic ovary syndrome (PCOS) affects 6.6-6.8% of women in reproductive age. Insulin resistance and hyperinsulinemia play a critical role in the pathogenesis of PCOS and are associated with a high risk for type 2 diabetes mellitus and cardiometabolic abnormalities. Metformin has been introduced as a therapeutic option in PCOS, targeting of cardiometabolic and reproductive abnormalities on the basis of its action on the reduction of glucose levels and the attenuation of insulin resistance. The tissue-specific actions of metformin as well as the molecular mechanisms involved in the liver, the muscle, the endothelium, and the ovary are elucidated in this review. The use of metformin in pregnant women with PCOS is another of its positive features. Overall, available data supports the therapeutic usefulness of metformin on cardiometabolic risk and reproduction assistance in PCOS women. |
| | |
Authors:
|
Evanthia Diamanti-Kandarakis; Frangiskos Economou; Sotiria Palimeri; Charikleia Christakou |
Publication Detail:
|
Type: Evaluation Studies; Journal Article; Review |
Journal Detail:
|
Title: Annals of the New York Academy of Sciences Volume: 1205 ISSN: 1749-6632 ISO Abbreviation: Ann. N. Y. Acad. Sci. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-15 Completed Date: 2010-09-28 Revised Date: 2010-10-19 |
Medline Journal Info:
|
Nlm Unique ID: 7506858 Medline TA: Ann N Y Acad Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 192-8 Citation Subset: IM |
Copyright Information:
|
© 2010 New York Academy of Sciences. |
Affiliation:
|
Third Department of Medicine, Endocrine Unit, Medical School University of Athens, Sotiria General Hospital, Greece. akandara@otenet.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cardiovascular Diseases
/
etiology,
metabolism Female Humans Hypoglycemic Agents / adverse effects, therapeutic use Infertility, Female / drug therapy, etiology, metabolism Metabolic Diseases / etiology, metabolism Metformin / adverse effects, pharmacology, therapeutic use* Polycystic Ovary Syndrome / complications, drug therapy*, metabolism Pregnancy |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 657-24-9/Metformin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Peroxisome proliferator-activated receptor-γ and -δ polymorphisms in women with polycystic ovary s...
Next Document: Evidence-based management of poor ovarian response.